Abstract
AMP is an allosteric inhibitor of human muscle and liver
fructose-1,6-bisphosphatase (FBPase). Despite strong
similarity of the nucleotide binding domains, the muscle enzyme is inhibited by AMP approximately 35 times
stronger than liver FBPase:
I0.5 for muscle and for liver FBPase are 0.14 uM and 4.8 uM, respectively. Chimeric
human muscle (L50M288) and chimeric human liver enzymes (M50L288), in which the N-terminal residues
(1-50) were derived from the human liver and human
muscle FBPases, respectively, were inhibited by AMP
2-3 times stronger than the wild-type liver enzyme. An
amino acid exchange within the Nterminal region of
the muscle enzyme towards liver FBPase (Lys20→Glu)
resulted in 13-fold increased
I0.5 values compared to the
wild-type muscle enzyme. However, the opposite exchanges in the liver enzyme (Glu20→Lys and double
mutation Glu19→Asp/Glu20→Lys) did not change the
sensitivity for AMP inhibition of the liver mutant (I0.5 value of 4.9 uM). The decrease of sensitivity for AMP of the
muscle mutant Lys20→Glu, as well as the lack of
changes in the inhibition by AMP of liver mutants
Glu20→Lys and Glu19→Asp/Glu20→Lys, suggest a different mechanism of AMP binding to the muscle and
liver enzyme.